Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

Sponsor
Novartis Korea Ltd.
Study ID
NCT00942864
Phase
PHASE3
Status
Completed

Conditions

  • Macular Edema
  • Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab — DRUG
    ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor

Study Details

The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).

Key Dates

First listed
Jul 21, 2009
Start date
Dec 31, 2008
Status verified
Sep 2016
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009

Study Design

Enrollment
40 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

The change in ETDRS visual acuity letter scores from baseline. The change in the 1-mm central retinal thickness as measured by OCT from baseline. [ Time Frame: every 4 weeks (up to 52 weeks) ]

Related Studies